Nuclear factor-κB inhibition provides additional protection against ischaemia/reperfusion injury in delayed sevoflurane preconditioning
European Journal of Anaesthesiology, ISSN: 0265-0215, Vol: 26, Issue: 6, Page: 496-503
2009
- 28Citations
- 19Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations28
- Citation Indexes28
- 28
- CrossRef17
- Captures19
- Readers19
- 19
Article Description
Background and objective Sevoflurane anaesthetic preconditioning (SPC) has been shown to limit nuclear factor-κB (NF-κB) activation and the production of inflammatory cytokines during myocardial ischaemia/ reperfusion (I/R). Similarly, pharmacological inhibition of NF-κB using parthenolide is effective in limiting I/R injury. We, therefore, postulated that the protective effect of delayed SPC would be enhanced by pharmacological NF- κB inhibition during I/R. Methods Hearts from 2-month-old male Fisher 344 rats were exposed to 25 min global ischaemia followed by 60 min reperfusion. Rats were divided into four groups prior to I/R: control group; parthenolide group, treated with the IκB kinase inhibitor parthenolide intraperitoneally 10 min prior to heart isolation; SPC group, treated for 60 min with sevoflurane 48 h prior to heart isolation; and SPC + parthenolide group, treated with SPC for 1 h followed by parthenolide 48 h later. Infarct area, left ventricular function and Ca,- were measured after I/R. Results Delayed SPC + parthenolide resulted in greater protection than either intervention alone, resulting in a significant reduction in infarct area and left ventricular developed pressure (mmHg; 84 ± 19 compared with 15 ± 14 in control hearts; P = 0.007). Left ventricular end- diastolic pressure also remained close to baseline values (9 ± 2 mmHg, P = 0.02) during I/R, and the increase in Ca,- seen with I/R was significantly blunted (P = 0.005). Conclusion SPC followed by parthenolide provides a significant protection from I/R injury in this model. As each intervention alone limits NF-κB activation with I/R, these data are consistent with additive effects of these dual modalities in limiting I/R injury due to NF-κB activation. © 2009 European Society of Anaesthesiology.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=68849121799&origin=inward; http://dx.doi.org/10.1097/eja.0b013e328324ed2e; http://www.ncbi.nlm.nih.gov/pubmed/19445059; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00003643-200906000-00009; http://journals.lww.com/00003643-200906000-00009; https://dx.doi.org/10.1097/eja.0b013e328324ed2e; https://journals.lww.com/ejanaesthesiology/Fulltext/2009/06000/Nuclear_factor__B_inhibition_provides_additional.9.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know